Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 31 04:00PM ET
3.08
Dollar change
-0.25
Percentage change
-7.51
%
IndexRUT P/E- EPS (ttm)-2.01 Insider Own39.25% Shs Outstand49.18M Perf Week-15.38%
Market Cap217.32M Forward P/E- EPS next Y-1.60 Insider Trans-0.03% Shs Float42.86M Perf Month-26.14%
Income-107.91M PEG- EPS next Q-0.37 Inst Own64.48% Short Float24.31% Perf Quarter-48.41%
Sales0.00M P/S- EPS this Y32.57% Inst Trans7.83% Short Ratio16.97 Perf Half Y-59.10%
Book/sh6.42 P/B0.48 EPS next Y1.06% ROA-21.95% Short Interest10.42M Perf Year51.72%
Cash/sh4.60 P/C0.67 EPS next 5Y- ROE-27.99% 52W Range1.89 - 16.24 Perf YTD-53.33%
Dividend Est.- P/FCF- EPS past 5Y-209.81% ROI-20.24% 52W High-81.03% Beta0.82
Dividend TTM- Quick Ratio15.91 Sales past 5Y-39.65% Gross Margin- 52W Low62.96% ATR (14)0.33
Dividend Ex-Date- Current Ratio15.91 EPS Y/Y TTM21.46% Oper. Margin0.00% RSI (14)29.17 Volatility9.31% 8.36%
Employees150 Debt/Eq0.19 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price17.17
Option/ShortYes / Yes LT Debt/Eq0.18 EPS Q/Q49.96% Payout- Rel Volume1.34 Prev Close3.33
Sales Surprise- EPS Surprise27.94% Sales Q/Q- EarningsAug 13 AMC Avg Volume614.08K Price3.08
SMA20-19.17% SMA50-33.71% SMA200-57.26% Trades Volume823,484 Change-7.51%
Date Action Analyst Rating Change Price Target Change
Oct-09-24Initiated Rodman & Renshaw Buy $14
Aug-14-24Upgrade Raymond James Outperform → Strong Buy $16
Mar-22-24Downgrade Raymond James Strong Buy → Outperform $13 → $16
Dec-22-22Downgrade Oppenheimer Outperform → Perform
Oct-10-22Initiated Canaccord Genuity Buy $25
Jul-28-22Initiated Needham Buy $26
Jul-18-22Initiated SVB Leerink Outperform $30
Mar-11-22Initiated Raymond James Outperform $17
Mar-08-22Initiated H.C. Wainwright Buy $25
Jan-06-22Initiated William Blair Outperform
Oct-09-24 08:00AM
Sep-03-24 04:01PM
Aug-14-24 12:37PM
Aug-13-24 09:03PM
04:01PM
06:00AM Loading…
Jul-24-24 06:00AM
Jul-16-24 06:01AM
Jul-10-24 12:00PM
Jul-01-24 10:20AM
Jun-27-24 06:00AM
Jun-13-24 04:01PM
May-10-24 02:56PM
May-09-24 10:57PM
04:01PM
May-07-24 06:30AM
04:02PM Loading…
Apr-03-24 04:02PM
Mar-25-24 04:06PM
06:30AM
Mar-23-24 05:31AM
Mar-22-24 04:03PM
09:18AM
Mar-21-24 10:54PM
04:01PM
Mar-19-24 07:29AM
Feb-29-24 06:30AM
Feb-28-24 08:01AM
Feb-20-24 04:19PM
Feb-08-24 09:32AM
Feb-06-24 12:50PM
Feb-05-24 12:41PM
08:00AM Loading…
Feb-04-24 08:00AM
Jan-09-24 10:25AM
Dec-09-23 08:31PM
Dec-08-23 12:00PM
Nov-14-23 03:56PM
Nov-09-23 04:02PM
11:38AM
Nov-07-23 08:02AM
Oct-25-23 02:06PM
Oct-18-23 10:47AM
01:18AM
Oct-17-23 08:17PM
11:47AM
07:01AM
Oct-16-23 04:01PM
Oct-02-23 03:07PM
Aug-10-23 07:01AM
Aug-03-23 08:02AM
Jul-31-23 06:30PM
Jul-05-23 04:02PM
Jun-28-23 09:35AM
Jun-27-23 01:02PM
07:01AM
Jun-26-23 04:01PM
Jun-15-23 09:55AM
Jun-10-23 10:47AM
May-11-23 04:02PM
04:01PM
May-09-23 07:15AM
May-07-23 12:50PM
Apr-17-23 05:01PM
Apr-12-23 09:06PM
Apr-11-23 09:46AM
Mar-30-23 04:01PM
Mar-16-23 04:01PM
Feb-17-23 05:35AM
Feb-09-23 08:02AM
Jan-09-23 04:30PM
Dec-05-22 07:02AM
Dec-02-22 04:02PM
Nov-09-22 04:02PM
Nov-07-22 08:52AM
Nov-02-22 08:02AM
Sep-24-22 09:34AM
Sep-23-22 07:30AM
Aug-11-22 04:02PM
Aug-10-22 08:42AM
Aug-07-22 06:15AM
Jul-25-22 04:31PM
Jul-18-22 02:46PM
Jun-14-22 07:14AM
Jun-07-22 09:55AM
May-31-22 07:02AM
May-18-22 12:00PM
09:55AM
May-16-22 04:02PM
May-12-22 04:02PM
May-09-22 04:02PM
May-06-22 05:30PM
May-02-22 10:45AM
Apr-28-22 04:01PM
10:18AM
Apr-25-22 11:19PM
06:04PM
05:44PM
04:09PM
04:01PM
03:52PM
10:49AM
08:34AM
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hager Alicia J.Chief Legal OfficerJul 16 '24Sale8.003,39627,168103,819Jul 18 04:22 PM
Trager JamesChief Scientific OfficerJun 18 '24Sale5.604562,554150,959Jun 20 05:04 PM
HASTINGS PAUL JChief Executive OfficerJun 18 '24Sale5.601,7709,912240,737Jun 20 05:03 PM
Shook DavidChief Medical OfficerJun 18 '24Sale5.604562,554116,524Jun 20 05:03 PM
Hager Alicia J.Chief Legal OfficerJun 18 '24Sale5.607274,071107,215Jun 20 05:02 PM
Brandenberger RalphChief Technical OfficerJun 18 '24Sale5.602291,28279,743Jun 20 05:01 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 27 '24Buy10.003,000,00030,000,00010,050,818Mar 29 05:38 PM
George SimeonDirectorMar 27 '24Buy10.002,000,00020,000,0001,548,341Mar 28 04:30 PM
Brandenberger RalphChief Technical OfficerMar 01 '24Option Exercise3.896,76326,30888,339Mar 05 04:26 PM
Brandenberger RalphChief Technical OfficerMar 01 '24Sale12.518,367104,67179,972Mar 05 04:26 PM
Trager JamesChief Scientific OfficerFeb 12 '24Sale12.004,14349,716149,415Feb 14 09:12 PM
Shook DavidChief Medical OfficerJan 16 '24Sale8.743,55231,044114,980Jan 18 04:45 PM
Trager JamesChief Scientific OfficerJan 16 '24Sale8.744,56039,854153,558Jan 18 04:43 PM
Brandenberger RalphChief Technical OfficerJan 16 '24Sale8.742,51221,95581,576Jan 18 04:40 PM
HASTINGS PAUL JChief Executive OfficerJan 16 '24Sale8.749,69784,752390,507Jan 18 04:40 PM
Hager Alicia J.Chief Legal OfficerJan 16 '24Sale8.744,55439,802107,942Jan 18 04:38 PM
Last Close
Oct 31 04:00PM ET
16.60
Dollar change
-0.27
Percentage change
-1.60
%
PCRX Pacira BioSciences Inc daily Stock Chart
IndexRUT P/E12.90 EPS (ttm)1.29 Insider Own3.33% Shs Outstand46.48M Perf Week-2.47%
Market Cap765.71M Forward P/E5.63 EPS next Y2.95 Insider Trans-0.33% Shs Float44.59M Perf Month6.89%
Income63.59M PEG1.19 EPS next Q0.70 Inst Own107.79% Short Float13.77% Perf Quarter-21.92%
Sales690.31M P/S1.11 EPS this Y6.32% Inst Trans6.12% Short Ratio5.51 Perf Half Y-39.24%
Book/sh19.07 P/B0.87 EPS next Y-1.37% ROA3.99% Short Interest6.14M Perf Year-41.26%
Cash/sh8.76 P/C1.89 EPS next 5Y10.80% ROE7.54% 52W Range11.16 - 35.95 Perf YTD-50.80%
Dividend Est.- P/FCF4.14 EPS past 5Y- ROI4.19% 52W High-53.82% Beta0.83
Dividend TTM- Quick Ratio5.70 Sales past 5Y15.46% Gross Margin65.75% 52W Low48.69% ATR (14)0.67
Dividend Ex-Date- Current Ratio6.82 EPS Y/Y TTM1451.33% Oper. Margin14.65% RSI (14)52.73 Volatility3.71% 3.96%
Employees712 Debt/Eq0.74 Sales Y/Y TTM3.15% Profit Margin9.21% Recom2.78 Target Price18.50
Option/ShortYes / Yes LT Debt/Eq0.73 EPS Q/Q-21.44% Payout0.00% Rel Volume0.51 Prev Close16.87
Sales Surprise2.47% EPS Surprise27.34% Sales Q/Q5.05% EarningsNov 06 AMC Avg Volume1.11M Price16.60
SMA20-0.46% SMA508.44% SMA200-30.52% Trades Volume573,104 Change-1.60%
Date Action Analyst Rating Change Price Target Change
Aug-13-24Downgrade Truist Buy → Sell $30 → $8
Aug-12-24Downgrade RBC Capital Mkts Outperform → Sector Perform $37 → $14
Aug-12-24Downgrade Raymond James Outperform → Mkt Perform
Aug-12-24Downgrade Piper Sandler Overweight → Neutral $42 → $11
Aug-12-24Downgrade JP Morgan Overweight → Underweight $45 → $10
Jul-03-24Downgrade Barclays Overweight → Equal Weight $38 → $25
Mar-07-24Resumed JP Morgan Overweight $80 → $45
Dec-20-23Initiated Raymond James Outperform $42
Aug-03-23Upgrade TD Cowen Market Perform → Outperform $50
Jan-31-23Resumed Wedbush Outperform $88 → $60
Oct-30-24 08:00AM
Oct-21-24 08:38AM
08:00AM
Oct-07-24 08:00AM
Oct-03-24 08:00AM
08:00AM Loading…
Sep-26-24 08:00AM
Sep-25-24 08:15AM
Sep-09-24 04:00PM
Aug-09-24 03:21PM
Jul-31-24 10:49AM
Jul-30-24 08:58PM
04:14PM
04:00PM
Jul-29-24 06:00AM
Jul-23-24 08:00AM
03:52AM Loading…
03:52AM
Jul-17-24 09:50AM
Jul-12-24 10:41AM
Jul-10-24 04:19PM
Jun-14-24 02:41AM
Jun-06-24 11:31AM
May-30-24 08:00AM
May-10-24 07:00AM
May-08-24 04:05PM
11:35AM
09:33AM
03:47AM
May-07-24 09:01PM
06:03PM
05:30PM
04:13PM Loading…
04:13PM
04:00PM
08:00AM
Apr-30-24 08:00AM
Apr-04-24 11:33AM
Apr-02-24 08:00AM
Mar-14-24 08:23AM
Mar-13-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Mar-01-24 08:38AM
06:05AM
12:28AM
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
08:00AM
Feb-22-24 08:00AM
Feb-15-24 08:36AM
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
08:23AM
08:00AM
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GAUGLER DARYLChief Operating OfficerSep 13 '24Sale12.865006,430115,700Sep 13 08:29 PM
GAUGLER DARYLOfficerSep 13 '24Proposed Sale12.865006,430Sep 13 10:17 AM
BIGAL MARCELODirectorAug 16 '24Buy13.251,51220,03410,142Aug 19 08:25 AM
Brege LauraDirectorAug 16 '24Buy12.811,00012,81017,552Aug 19 08:25 AM
YANG MICHAEL J.DirectorAug 14 '24Buy12.902,00025,8007,230Aug 14 04:35 PM
Lee Frank D.Chief Executive OfficerAug 12 '24Buy12.108,26499,994107,784Aug 13 04:55 PM
Froimson MarkDirectorAug 12 '24Buy11.581,40016,21214,473Aug 12 08:33 PM
BIGAL MARCELODirectorAug 12 '24Buy12.013,40040,8348,630Aug 12 08:33 PM
SLONIN JONATHANChief Medical OfficerAug 02 '24Sale20.0594518,94794,307Aug 02 06:00 PM
SLONIN JONATHANOfficerAug 02 '24Proposed Sale20.0594518,947Aug 02 10:09 AM
SLONIN JONATHANChief Medical OfficerJul 02 '24Sale28.252,83680,11795,557Jul 03 06:52 PM
RIKER LAURENSenior Vice President, FinanceJun 12 '24Sale28.723,970114,01838,075Jun 13 06:15 PM
SLONIN JONATHANChief Medical OfficerJun 11 '24Sale28.575,012143,19344,569Jun 13 06:15 PM
GAUGLER DARYLChief Operating OfficerJun 13 '24Sale28.381,00028,380116,040Jun 13 06:13 PM
HASTINGS PAUL JDirectorJun 13 '24Sale28.3888024,97412,724Jun 13 06:13 PM
WILLIAMS KRISTENChief Administrative OfficerJun 13 '24Sale28.387,452211,488102,912Jun 13 06:12 PM
PACE GARY WDirectorMar 08 '24Sale30.6090,0002,754,00022,127Mar 08 05:33 PM
PACE GARY WDirectorMar 07 '24Sale30.8128,257870,598112,127Mar 08 05:33 PM
PACE GARY WDirectorMar 06 '24Sale29.671,06631,628140,384Mar 08 05:33 PM